Patents by Inventor Alessandra Luzzago

Alessandra Luzzago has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hepatitis C virus vaccine
    Patent number: 8142794
    Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: March 27, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca
  • Antigen binding proteins directed against scavenger receptor B1 that inhibit HCV replication
    Patent number: 7928193
    Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: April 19, 2011
    Assignee: Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli
  • Hepatitis C virus vaccine
    Patent number: 7598362
    Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: October 6, 2009
    Assignees: Merck & Co., Inc., Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca
  • HEPATITIS C VIRUS VACCINE
    Publication number: 20090233992
    Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
    Type: Application
    Filed: March 3, 2009
    Publication date: September 17, 2009
    Inventors: Emilio A. Emini, David C. Kaslow, Andrew J. Bett, John W. Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloen
  • Antigen Binding Proteins Directed Against Scavenger Receptor B1 that Inhibit Hcv Replication
    Publication number: 20080286275
    Abstract: The present invention features antigen binding protein that bind to a SR-BI target region identified herein as a region involved in HCV E2 binding. Identified target regions are regions bound by a single-chain antibody of SEQ ID NOs: 1, 2, 3 or 4.
    Type: Application
    Filed: July 1, 2005
    Publication date: November 20, 2008
    Inventors: Riccardo Cortese, Alessandra Luzzago, Alfredo Nicosia, Alessandra Vitelli
  • Hepatitis c virus vaccine
    Publication number: 20040247615
    Abstract: The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.
    Type: Application
    Filed: April 7, 2004
    Publication date: December 9, 2004
    Inventors: Emilio A Emini, David C Kaslow, Andrew J Bett, John W Shiver, Alfredo Nicosia, Armin Lahm, Alessandra Luzzago, Riccardo Cortese, Stefano Colloca
  • Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
    Patent number: 6541210
    Abstract: A process for the preparation of immunogens or diagnostic reagents that mimic an antigen or a pathogenic organism specific to a disease, essentially characterized by the following operations: identification of at least one antibody that reacts with the antigen or pathogenic organism specific to the disease; construction of phage libraries which display on the surface of the capsid oligopeptides, expressed from random sequence oligonucleotidic inserts introduced into a gene coding for a phage capsid protein using genetic manipulation techniques (for example, using a plasmid engineered for the purposes of the invention, the genetic map of which is shown in the figure); selection of the phages that display on the surfaces of the capsid antigenic oligopeptides recognized by said antibody; optional use of the selected phages and/or fragments thereof and/or their derivatives for the formulation of diagnostic kits for the specific pathogenic agent, or in general for the disease, including immunological disorders typ
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: April 1, 2003
    Assignee: Istituto di Recerche di Biologia Moleculare P. Angeletti S.p.A.
    Inventors: Franco Felici, Alessandra Luzzago, Paolo Monaci, Alfredo Nicosia, Riccardo Cortese
  • Process for the preparation of immunogens or diagnostic reagents, and immunogens or diagnostic reagents thereby obtainable
    Patent number: 5994083
    Abstract: A process for the preparation of immunogens or diagnostic reagents that mimic an antigen or a pathogenic organism specific to a disease, essentially characterized by the following operations: identification of at least one antibody that reacts with the antigen or pathogenic organism specific to the disease; construction of phage libraries which display on the surface of the capsid oligopeptides, expressed from random sequence oligonucleotidic inserts introduced into a gene coding for a phage capsid protein using genetic manipulation techniques (for example using a plasmid engineered for the purposes of the invention, the genetic map of which is shown in the figure); selection of the phages that display on the surfaces of the capsid antigenic oligopeptides recognized by said antibody; optional use of the selected phages and/or fragments thereof and/or their derivatives for the formulation of diagnostic kits for the specific pathogenic agent, or in general for the diseases, including immunological disorders typ
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: November 30, 1999
    Assignee: Istituto di Recerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Franco Felici, Alessandra Luzzago, Paolo Monaci, Alfredo Nicosia, Riccardo Cortese